BioSense Webster

St. Jude Medical banks $170M on contact force ablation tech in growing A-fib market

As predicted, the next incremental advances in the growing A-fib heart space may very well be in contact force catheter technology. St. Jude’s Medical is banking on it. The company just acquired Endosense, a Switzerland company that creates contact force ablation catheter technology, for $170 million. If Endosense meets an undisclosed regulatory milestone, it could […]

Atricure enrolls first patient in atrial fibrillation trial

Cardiac medical device maker AtriCure Inc. (NASDAQ:ATRC) has enrolled the first patient in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhythm. The procedure being evaluated in the study combines AtriCure's minimally invasive surgical ablation devices with a catheter-based ablation system from BioSense Webster, a Johnson & Johnson company.